ARTERIOVENOUS FISTULA SITE COMPLICATION

This adverse event was reported 600 times

These drugs are most commonly taken by patients reporting ARTERIOVENOUS FISTULA SITE COMPLICATION:

# Drug Count
0 DARBEPOETIN ALFA 238
1 SEVELAMER HYDROCHLORIDE 33
2 CINACALCET HYDROCHLORIDE 31
3 EPOETIN ALFA 31
4 ASPIRIN 30
5 ASPIRIN 325 MG 29
6 ASPIRIN 81 MG 29
7 ECULIZUMAB 28
8 PARICALCITOL 28
9 CINACALCET 26
See all common drugs associated with ARTERIOVENOUS FISTULA SITE COMPLICATION

ARTERIOVENOUS FISTULA SITE COMPLICATION is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PETROLATUM AND RESORCINOL 1 0.1000
1 SEVELAMER HYDROCHLORIDE 33 0.0575
2 HEPATITIS B IMMUNE GLOBULIN (HUMAN) 1 0.0196
3 MINERAL OIL, WHITE PETROLATUM 2 0.0069
4 AMLODIPINE AND VALSARTAN 1 0.0051
5 DARBEPOETIN ALFA 238 0.0044
6 EPOETIN ALFA 31 0.0026
7 BRIMONIDINE TARTRATE AND TIMOLOL MALEATE 1 0.0025
8 HYDRALAZINE HYDROCHLORIDE AND ISOSORBIDE DINITRATE 1 0.0023
9 PARICALCITOL 28 0.0020
See all drugs enriched for association with ARTERIOVENOUS FISTULA SITE COMPLICATION

ARTERIOVENOUS FISTULA SITE COMPLICATION is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Human Immunoglobulin [EPC] 1 0.0196
1 Erythropoiesis-stimulating Agent [EPC] 238 0.0044
2 Vitamin D2 Analog [EPC] 28 0.0039
3 Vitamin D Analog [EPC] 28 0.0016
4 Carnitine Analog [EPC] 5 0.0014
5 Vitamin D3 Analog [EPC] 11 0.0005
6 Skin Test Antigen [EPC] 1 0.0005
7 Parenteral Iron Replacement [EPC] 7 0.0005
8 Complement Inhibitor [EPC] 28 0.0005
9 Guanylate Cyclase-C Agonist [EPC] 1 0.0005
See all drug classes enriched for association with ARTERIOVENOUS FISTULA SITE COMPLICATION